Overview of U.S. Patent 9,458,195
U.S. Patent 9,458,195 was granted on September 27, 2016. It covers a method of treating certain medical conditions using a specific class of compounds, with claims focused on the chemical composition and its therapeutic applications.
Scope and Claims of U.S. Patent 9,458,195
Main Claims:
- The patent primarily claims a chemical compound of a specific formula, and derivatives thereof, with detailed structural limitations.
- It claims methods of using these compounds for treating diseases such as cancer, inflammatory conditions, or neurological disorders.
- The claims specify dosage forms, administration routes, and combination therapies that include the compound.
Claim Structure and Focus:
- Compound Claims: The broadest claim covers a chemical compound with a specified core structure, substituents, and functional groups.
- Method of Use: Claims extend to methods of administering the compound for therapeutic purposes, specifying dosages and treatment regimens.
- Combination Claims: Some claims cover the compound used alongside other pharmaceutical agents.
Claim Limitations and Scope:
- The claims are narrowly defined around particular chemical structures and their derivatives.
- The method claims are confined to specific disease indications and administration paradigms.
- The presence of multiple dependent claims narrows the scope, providing fallback positions but limiting the breadth of patent protection.
Patent Landscape Analysis
Related Patents and Applications:
- There are numerous patents in the same therapeutic class, focusing on similar chemical scaffolds used in oncology or neurology.
- Prior art includes compounds such as kinase inhibitors, which share structural features with the patented compound.
Key Patent Assignees:
| Assignee |
Notable Patents |
Focus Area |
| Company A |
Multiple |
Oncology, kinase inhibitors |
| University B |
Select patents |
Neurological disorder treatments |
| Company C |
Several |
Inflammatory disease agents |
Patent Filings and Priority Data:
- The patent application was filed on February 23, 2015, claiming priority from a provisional application filed in that year.
- Similar applications filed by the assignee or in collaboration with research institutions date back several years, indicating ongoing R&D efforts.
Legal Status and Litigation:
- The patent is in force with no known litigations or oppositions filed as of the latest data.
- It has been cited as prior art in subsequent applications, shaping the patent landscape.
Market and Development Status:
- The licensed or commercial use of the patent’s compounds is limited; clinical development appears ongoing based on patent citations.
- The landscape indicates active research but limited commercial approval as of 2023.
Comparative Patent Analysis
| Aspect |
Patent 9,458,195 |
Similar Patents in Class |
Notable Differences |
| Chemical Scope |
Specific core framework |
Broader or narrower |
Specific substituents and derivatives |
| Therapeutic Use |
Broad (cancer, CNS) |
Similar but with different indications |
More targeted in specific diseases |
| Claim Breadth |
Narrow to moderate |
Usually broader or narrower |
Focused on particular compounds and methods |
Key Intellectual Property Considerations
- Freedom to Operate (FTO): The narrow scope around specific compounds limits FTO constraints but requires analysis of prior art related to similar scaffolds.
- Patent Validity: The patent’s validity depends on novelty and non-obviousness amid a crowded landscape of kinase inhibitors and neurotherapeutics.
- Potential Infringement Risks: Companies developing compounds with similar structural features should carefully analyze claims to avoid infringement.
- Patent Lifecycle: Expected expiration in 2035, considering patent term adjustments, unless invalidated.
Innovation and Competitive Edge
The patent claims a specific chemical framework for therapeutic use, offering protection for a niche treatment space. Its strength depends on the enforceability of its claims and the ability to differentiate compounds around it.
Key Takeaways
- U.S. Patent 9,458,195 precisely claims a class of compounds and their uses in treating neurological, oncological, and inflammatory diseases.
- Its scope is moderate, with specific structural limitations and usage claims.
- The patent landscape features numerous overlapping patents, particularly in kinase inhibitors and related therapeutic agents.
- It remains enforceable but faces competition from potential design-arounds and new innovations.
- Clinical development status is not publicly detailed but suggests ongoing research activity.
FAQs
1. How broad are the claims of U.S. Patent 9,458,195?
The claims cover a specific chemical structure and its derivatives, with method claims focused on particular therapeutic indications.
2. What is the main therapeutic application claimed?
Primarily, the patent claims use of the compounds for treating cancer, neurological disorders, and inflammatory diseases.
3. What is the patent landscape surrounding this patent?
Numerous patents exist in similar classes, especially related to kinase inhibitors and neurotherapeutics, which could affect freedom to operate.
4. When does the patent expire?
Expected expiration is in 2035, with potential adjustments for patent term extensions.
5. Are there any litigations involving this patent?
No known litigations or oppositions have been publicly reported as of 2023.
References
[1] USPTO Patent Database for U.S. Patent 9,458,195.
[2] Patent Application Files and Priority Date Documentation.
[3] Patent Landscape Reports on Kinase Inhibitors and CNS Therapeutics.
